Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
📧 Sign up to get email alerts when something new happens for Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-07Clinical Trial Update: Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis [Phase 2]
This update notes that a Phase 2 trial evaluating Tarperprumig for safety and efficacy in adults with ANCA-associated vasculitis is currentl…
-
CLINICAL_TRIALS trial_result · 2023-08-01Clinical Trial Update: Stratified Therapy on Pediatric AAGN [Phase 4]
A Phase 4 clinical trial update investigating stratified therapy for pediatric ANCA-associated vasculitis and ANCA-associated glomerulonephr…
-
CLINICAL_TRIALS trial_result · 2023-07-27Clinical Trial Update: Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing [Phase 4]
Phase 4 trial on intermittent rituximab dosing for maintaining remission in ANCA vasculitis; study terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2022-03-18Clinical Trial Update: Rituximab Vasculitis Maintenance Study [Phase 3]
Phase 3 clinical trial update for rituximab maintenance in ANCA-associated vasculitis, including microscopic polyangiitis and Wegener granul…
-
CLINICAL_TRIALS trial_result · 2021-01-27Clinical Trial Update: Low-dose Glucocorticoid Vasculitis Induction Study [Phase 4]
Phase 4 clinical trial update investigating low-dose glucocorticoids for induction in vasculitis conditions.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.